HER3-DXd在EGFR-TKI耐药癌症中具有临床活性,独立于耐药机制,为治疗多种耐药癌症提供了一种方法。 SIGNIFICANCE 意义 In metastatic EGFR-mutated NSCLC, after disease progression on EGFR TKI therapy, treatment approaches include geno...
在今年的世界肺癌大会(WCLC)上,一款HER3靶点的抗体-药物偶联物(ADC)Patritumab Deruxtecan(HER3-DXd,U3-1402),更新了其在EGFR突变非小细胞肺癌患者当中的疗效。其中有209例患者是已经对第三代EGFR抑制剂及铂类化疗耐药的患者,整体缓解率接近30%! 奥希替尼耐药,缓解率仍有约30% 根据报告,在Ⅱ期HERTHENA-Lung...
Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate combining an anti-HER3 antibody with a topoisomerase I inhibitor. It has demonstrated promising results in mBC and EGFR-mutated NSCLC, as shown in the HERTHENA-Lung 01 study, in which a CNS objective response rate (ORR) of ...
Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice. This is a modal window. The Playback API request failed for ...
Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC EP: 6.Future Perspectives in ADCs for Treating Advanced NSCLC EP: 7.Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC EP: 8.Increasingly Targeted ADCs Drive N...
The collaboration will focus on clinical and translational research, including potential combination strategies for DS-1062, a TROP2 directed DXd ADC, in patients with advanced non-small cell lung cancer (NSCLC), and for patritumab deruxtecan, a HER3 directed DXd ADC, in patients with metastatic...
Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advancedEGFR-mutated NSCLC.doi:10.1200/JCO.2022.40.16_suppl.TPS316133TPS3161#Background:Although first-line treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase ...
P01.03 Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLCdoi:10.1016/j.jtho.2021.01.327P. JnneR. RajagopalanG. PudusseryP. Shrestha...
The collaboration will focus on clinical and translational research, including potential combination strategies for DS-1062, a TROP2 directed DXd ADC, in patients with advanced non-small cell lung cancer (NSCLC), and for patritumab deruxtecan, a HER3 directed DXd ADC, in patients with metastatic...